2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Checkpoint Inhibitor, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Clinical Research, Patient-Reported Outcomes, Study Population, Human, Adult, Elderly, Young Adult
PAPER

2062 U2AF1 mutation defines an early onset MDS sub-population in Asian patients characterized by premature aging

Ruoyang Shao, MD, PhD, Yueyang Zhong2, Yuxin Bai3, Kejing Li4, Zhonghui Jiang5, MIN Dai6, Ling Jiang7, Hua Jin8, Jing Sun9, Qifa Liu, MD10, Xuan Li, PhD11
1 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
2 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
3 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
4 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
5 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
6 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
7 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
8 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
9 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
10 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
11 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Myelodysplastic syndromes (MDS) are age-associated hematopoietic neoplasms that predominantly affect older adults. However, several Asian cohorts have reported a younger age at diagnosis compared with that in Western cohorts. The mechanism of this age discrepancy remains unclear.

To explore the biological mechanism behind the younger age at diagnosis in Asian patients with MDS, bone marrow aspirates were collected from 83 patients for single-cell RNA sequencing (scRNA-seq) aging from 20 to 92 years. As MDS arises from clonally altered hematopoietic stem and progenitor cells, age-related changes in hematopoietic stem cell (HSC) biology may be particularly relevant to disease pathogenesis. Therefore, we integrated 10 public scRNA-seq bone marrow datasets from healthy donors aged 18 to 84 years to establish a reference for HSC aging. HSCs were identified and aggregated at the sample level to generate pseudo-bulk expression profiles. A healthy HSC aging model was constructed using consensus age-associated transcriptional signatures, including myeloid lineage bias, inflammaging, loss of proteostasis, reduced DNA repair capacity, and mitochondrial dysfunction. The model was trained to estimate HSC aging scores using the chronological ages of healthy donors and was then applied to patient-level pseudo-bulk profiles of MDS HSCs. HSC age acceleration is defined as the deviation between a patient’s HSC aging score and value based on the same chronological age in healthy populations. Patients were accordingly classified into accelerated-aging and non-accelerated-aging groups.

We found out that HSC aging scores were not significantly correlated with chronological age in MDS, revealing interpatient heterogeneity in the biological aging states of MDS HSCs. Comparative pathway enrichment analysis showed that accelerated HSC aging in MDS shared several features with physiological aging in healthy donors, such as activation of cellular senescence and chronic inflammatory response programs. However, telomere maintenance and DNA repair pathways were significantly downregulated in the accelerated-aging MDS group but were not significantly altered between the elderly and younger healthy donors. In addition, several splicing factor genes were upregulated specifically in the accelerated-aging MDS group. These findings suggest that accelerated HSC aging in MDS comprises both shared features of physiological aging and disease-specific molecular alterations.

To explore candidate genetic drivers of premature aging in HSC, we next examined the distribution of recurrent somatic mutations among the MDS aging groups. All three patients with U2AF1 mutations were classified into the accelerated-aging group, while no similar distribution was observed in other mutations. To further characterize the features associated with U2AF1 mutations, we then profiled eight additional MDS patients with U2AF1 mutations. Differential expression and pathway enrichment analysis comparing U2AF1-mutant and wild type patients exhibited downregulations of telomerase activity, HSC stemness, DNA repair and cell-cycle regulation, indicating a premature-aging phenotype associated with U2AF1 mutations.

As U2AF1 plays an important role in spliceosome, we hypothesized that U2AF1 mutations may contribute to premature HSC aging through aberrant RNA splicing. Alternative splicing analysis comparing U2AF1-mutant and wild type samples revealed increased intron retention in several genes involved in telomere maintenance and RNA splicing. To further validate whether U2AF1 mutations were associated with telomere attrition, telomere length was measured in MDS patients with U2AF1-mutant and wild type. U2AF1-mutant patients showed a trend toward shorter telomere length.

Taken together, our findings suggest that U2AF1 mutations are associated with premature HSC aging through impaired telomere maintenance and may represent one potential molecular contributor to the younger age at diagnosis of MDS in Asian populations.

Ruoyang Shao, MD, PhD: No relevant conflicts of interest to declare.